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A highly automated RT-PCR-based approach has been established to validate novel human gene predictions with no prior experimental
evidence of mRNA splicing (ab initio predictions). Ab initio gene predictions were selected for high-throughput validation using predicted protein
classification, sequence similarity to other genomes, colocalization with an MPSS tag, or microarray expression. Initial microarray prioritization
followed by RT-PCR validation was the most efficient combination, resulting in approximately 35% of the ab initio predictions being validated by
RT-PCR. Of the 7252 novel genes that were prioritized and processed, 796 constituted real transcripts. In addition, high-throughput RACE
successfully extended the 5′ and/or 3′ ends of N60% of RT-PCR-validated genes. Reevaluation of these transcripts produced 574 novel transcripts
using RefSeq as a reference. RT-PCR sequencing in combination with RACE on ab initio gene predictions could be used to define the
transcriptome across all species.
© 2005 Elsevier Inc. All rights reserved.Keywords: RT-PCR; Novel human genesAlthough the act of physically sequencing of the human
genome has been deemed complete for some time [1–3], the
task of accurately and completely identifying all human genes
still remains. The large scale of this endeavor has led
researchers to rely largely on computer algorithms to predict
sequences that constitute functional genes [4–6]; however,
computer predictions, particularly when used without the
benefit of experimental data, can often mispredict the 5′ and
3′ ends of genes and miss a lot of exons.
The problems with gene prediction algorithms are well
known [7–10]. They use a variety of methods to predict the
likelihood that a sequence constitutes a gene, for example by
identifying homology to existing known genes, identifying
consensus sequences (e.g., promoter elements, start and stop⁎ Corresponding author. Fax: +1 650 638 6893.
E-mail address: samaharr@appliedbiosystems.com (R.R. Samaha).
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doi:10.1016/j.ygeno.2005.11.016codons, splice sites, and poly(A) sites) [11], and using statistical
analysis of oligonucleotide frequency, exon and intron length,
and intron and exon number [8]. Algorithms that use sequence
features to predict gene structure typically predict fewer than
50% of known exons and 20% of complete genes [6]. Recently,
however, new algorithms that use sequence conservation
between distantly related genomes have been developed.
These dual genome predictors have had a higher rate of success
in correctly predicting exons and known genes than single
genome predictors [12,13], though to be effective, these
approaches require the sequence of related organisms, which
need to be separated by an appropriate evolutionary gap.
Other approaches have relied on homology to known
expressed sequences (typically expressed sequence tags
(ESTs)) to identify and annotate genes [14]. ESTs have been
used successfully to identify genes, especially with recent
advances in clustering algorithms [15–17]. Although often
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sequences are more accurate at predicting exons of known
genes. Nevertheless, these approaches are obviously dependent
on the existence of expression data and further tend to miss
many predicted exons and genes expressed at low levels. They
are also prone to contamination from genomic sequences and
unspliced mRNAs [3,18].
Additional experimentally based approaches involve fully
sequencing cDNAs and then using clustering algorithms to
reconstitute individual genes. For example, Imanishi et al.
sequenced over 41,000 human cDNAs that they subsequently
determined represented over 21,000 genes, including over 5000
newly identified gene candidates [19]. Despite the success of
this method, the cDNA approach is susceptible to the low
processivity of reverse transcriptase and can result in incom-
plete gene sequences, particularly for long genes. Therefore,
additional experimental approaches are needed to discover the
true ends of genes and provide a complete picture of gene
structure. To increase accuracy over automated approaches,
some groups have employed expert manual curators [20].
Although this approach can be very successful, it is also
dependent on availability of data and is relatively time
consuming. Therefore, efficient and automated experimental
approaches are critical to rapidly validate novel genes that have
not been predicted by bioinformatics approaches.
Other researchers have also come to the conclusion that
experimental validation of novel genes is necessary; some have
taken wide, microarray-based approaches to experimentally
characterize genes that have been predicted ab initio. For
example, “exon” and “tiling” arrays have been used to validate
and refine computational gene predictions and define full-length
transcripts on the basis of coregulated expression of their exons.
This first study was carried out in detail for chromosome 22q
and proved reliable for the detection of multiple splice variants
and for the detection of genes that are expressed under tissue- or
disease-specific conditions [21]. Later studies have focused on
chromosomes 21 and 22 using 25-mer oligonucleotide arrays
[22] as well as chromosomes 20 and 22 using 60-mer
oligonucleotide arrays [23]. These tiling approaches are
typically independent of computational predictions and have
been recently extended to cover a much larger portion of the
human genome [23,24]. Other microarray-based approaches
have used polymerase chain reaction (PCR)-amplified open
reading frames to validate gene predictions in 350 kb of large
human genomic clones [25]. These approaches have been quite
successful in generating a wealth of expression data that not
only have validated known genes but also, because of their
independence from genome annotation, have identified signif-
icant transcriptional activity outside of known gene boundaries
[23,24]. Such approaches, however, rely upon measuring the
intensity (or differences in intensity between samples) of
fluorescent probes hybridized to the array, a method with lower
sensitivity, which is also prone to a high degree of false
positives that are most often caused by cross-hybridization or
other experimental artifacts. In addition, to generate accurate
details of gene structure, a high tiling density is required, which
renders these experiments prohibitively expensive. On the otherhand, reverse transcription (RT)-PCR coupled with direct
sequencing of generated amplicons has been used to validate
predictions generated using dual genome algorithms for both
human [26] and rat [27], Genscan-predicted novel genes on
human chromosome 22 [10], and predicted open reading frames
in the Caenorhabditis elegans genome with a great measure of
success [28].
Our goal was to validate experimentally ab initio predictions
with low certainty scores (i.e., with little or no evidence beyond
the actual computational gene prediction) to gain a better view
of the completeness of the human transcriptome. Because we
were ultimately interested in designing TaqMan (PCR-based)
gene expression assays and microarray probes for these novel
transcripts, determining the correct gene structure was critical to
our endeavor. Using an approach that relies solely on
microarrays was deemed incomplete and we decided instead
to implement a high-throughput RT-PCR approach. Neverthe-
less, our previous experience validating a small number of ab
initio predictions with low certainty scores using RT-PCR
followed by amplicon sequencing (R. Samaha, unpublished
data) indicated that scaling up this process would be
prohibitively time consuming and costly, and the final
percentage of validated ab initio predictions would be relatively
low. Therefore, we decided to test a variety of bioinformatic and
experimental approaches to prioritize the ab initio predictions
that would be processed through our RT-PCR pipeline and
increase our final validation rate.
Ab initio predictions were prioritized on the basis of four
criteria: predicted protein classification using our proprietary
Panther pipeline [29], sequence similarity compared to dog or
mouse genomes, colocalization with a massively parallel
signature sequencing (MPSS) tag [30], or detection of
expression on microarrays (see Materials and methods).
Prioritized predictions were then validated using RT-PCR on a
series of mRNAs from 30 tissues followed by sequencing of the
resulting amplicons, a process that we refer to as the RT-PCR
pipeline. Additionally, we set up a high-throughput rapid
amplification of cDNA ends (RACE) pipeline to determine
additional 3′ and 5′ sequence of the predictions that had been
validated by our RT-PCR pipeline. In addition to increasing our
validation yields, the combination of these methods provided
information about gene structure, splice variants, and gene
boundaries that would not necessarily be obtainable using an
array-only approach. In this paper, we report on the novel genes
that were identified genome-wide from these high-throughput
experiments, which add to the annotated knowledge of the
transcriptome.
Results
Ultimately, after filtering, 7252 of the 98,545 ab initio
predictions were processed through the RT-PCR/sequencing
pipeline on 10 different tissue pools (Supplemental Data File 1).
Of those, 796 (12%) ab initio predictions were validated and
thus represent truly expressed, previously unidentified genes.
Prioritizing by expression on microarrays resulted in the highest
validation rate by RT-PCR (33%), whereas the RT-PCR
Fig. 1. Distribution of alternative splicing events among three tissue pools:
cancer, fetal, and other.
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dog and mouse varied from 15 to 3.8% (Table 1) and, as
expected, were correlated with the degree of similarity.
Validation rates for predictions prioritized by Panther classifi-
cation or colocalization with an MPSS tag were 21.3 and
18.5%, respectively (Table 1).
Although the in silico approaches required no wet lab work
and were therefore very efficient, they yielded lower validation
rates and had the disadvantage that only a small number of gene
predictions passed the filtering criteria. For example, of the
21,000 predictions processed, 1684 had a Panther classification
and only 313 were colocalized with an MPSS tag, severely
limiting the applicability of these approaches. On the other
hand, after optimizing the threshold by which we called a gene
present, using TaqMan data as controls, 33% of the predictions
profiled on microarrays ultimately were prioritized for RT-PCR
validation. The microarray prioritization approach was made
even more efficient by limiting profiling to 15 tissues.
An additional benefit of using microarrays as a prioritization
step (as opposed to the other bioinformatics-based filtering
methods) is their ability to reveal information about the genes’
tissue distribution. The expression levels were used to
determine which gene predictions were exclusively expressed
in the tissues used. For example, there were more than 60 genes
expressed exclusively in liver, whereas very few genes were
expressed exclusively in fetal heart, fetal kidney, kidney, or lung
(Supplemental Data File 2).
Using RT-PCR as the validation method also enabled us to
determine the intron/exon structure of the transcripts. For the
796 ab initio gene predictions that were validated, we
discovered 238 exons that were not previously identified by
the prediction software programs. The resulting transcripts were
compared to RefSeq, GenBank mRNA, and Ensembl cDNA.
Depending on the reference set, between 505 and 574 either
were entirely novel or provided novel exonic information to an
otherwise known transcript (163 and 296 were novel, the
remaining showed additional exonic information).
Moreover, the majority of ab initio gene predictions were
small (∼500 bp) compared to human curated RefSeqs (NM_
sequences) and Celera genes (hCTs) and had only one spliceTable 1
RT-PCR validation rates by prioritization category
Prioritization method RT-PCR
validation
rate (%)
Dog/mouse similarity N50% 15.0
Dog/mouse similarity 30–50% 17.0
Dog/mouse similarity 15–29% 3.8
Dog/mouse similarity b15% 5.2
Panther 21.3
MPSS 18.5
Arrays 32.0
Ab initio gene predictions that correlated to expressed genes on microarrays
gave the highest validation rate by RT-PCR. Predictions prioritized by MPSS tag
analysis and Panther software analysis were validated at intermediate levels.
When dog/mouse similarity was used, predictions were validated at rates that
correlated with the degree of similarity, as expected.site, suggesting that the gene ends had not been correctly
predicted (Supplemental Data File 3, unpublished data).
Therefore, most transcripts that were validated by RT-PCR
and sequencing were subjected to high-throughput extension by
5′ and 3′ RACE using the tissue pools we had found them to be
expressed in. This enabled us to extend the ends of the
transcripts and also identify new exons. Of the 687 genes
subjected to RACE and sequence analysis, 385 (56%) gave a
product. New 3′ ends or new 5′ ends were identified for 184 of
the 385 transcripts, and 191 new exons were discovered.
Overall, approximately 300,000 bp of new sequence was
generated.
We were also interested in the distribution of splice variants
of the validated gene predictions in the different tissue pools
that were used. These pools (Supplemental Data File 1) were
combined depending on their tissue origin into three different
categories: cancer template, fetal tissue template, and a normal
tissue template. Splice variants specific to each category were
determined by performing pair-wise comparisons of the variants
between each category. As expected [31], cancer pools
produced a significant number of alternative splicing events
(38%). However, the largest number of alternative splicing
events was observed for the fetal tissue category (57%),
whereas the remaining 5% were observed in the normal tissue
pools (Fig. 1). Overall, alternative splicing was identified for
253 (30%) of the 863 validated predictions.
Newly validated genes, including those that were extended
by RACE, were also reclassified using the Panther protein
classification software. Of the new genes, 261 had high
homology to genes from different functional classes, a subset
of which is listed in Table 2 (and Supplemental Data Files 4, 5,
and 6), indicating that these newly discovered genes might play
a significant role in important biological processes. For
example, we discovered 6 novel kinases, 32 novel transcription
factors, and 32 novel receptors.
Since this work was completed several months ago, we
recently compared the validated transcripts against the current
Ensembl v29 and NCBI RefSeq March dataset (release 10). Of
796 transcripts, 574 were still novel. We required 97% identity
and 90% overlap of two sequences in a BLASTn alignment to
be called identical. We found 156 sequences in Ensembl and
Table 2
Summary of validated predictions with Panther protein classifications
Panther software class Number
of genes
Receptors 32
Transcription factors 22
Defense/immunity 16
Kinases 6
Proteases 12
Chemokines/cytokines 8
Phosphatases 7
Cancer/oncogenesis 7
Cell division/cell cycle 7
Chromatin rearrangement 4
Transporters 4
Chaperones 3
Ubiquitin/proteasomes 3
Translation 3
Apoptosis 1
Splicing 1
After the ends of validated gene predictions were extended, many transcripts
could be assigned new classifications by the Panther software.
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of our approach.
Supplemental Data Files 4, 5, and 6 illustrate three examples
of novel genes that were discovered by our approach. Using
Celera’s Genome Browser we superimposed the original ab
initio gene prediction over the RT-PCR-generated contigs as
well as the RACE-extended contigs. One novel transcript had
significant homology, as determined by Panther classification,
to the Schlafen gene family, which is involved in T cell
development [32]. This prediction originally consisted of two
exons that were validated by RT-PCR; however, the splice
junction had been incorrectly predicted and a third new exon
was identified by the RT-PCR approach. Furthermore, using
RACE, we were able to extend this gene by three exons at the 3′
end.
Discussion
Predicted genes within the Celera genome have been
categorized based on the level of evidence that supports their
existence. Gene predictions using the OTTO algorithm [1] are
sequences with considerable supporting evidence, whereas the
genes predicted with the Promote software [1] have less
supporting evidence. These genes are classified into one of four
possible promote levels that indicate the pieces of evidence used
in the prediction. For example, a promote “1” has one piece of
evidence supporting it, and a promote “2” has two pieces of
evidence, and so on. Evidence can be an EST, or mouse
similarity, or similarity to a known protein [1]. Earlier validation
work (R. Samaha et al., unpublished) focusing on promotes,
using RT-PCR and sequencing, indicated that they were well
annotated, with validation rates ranging from 70 to 75%. This
result led us to the conclusion that, rather than validating
promotes that already have supporting evidence of their
existence, the greatest advancement of knowledge of the
transcriptome would come from focusing on ab initio genepredictions that do not qualify as promotes and therefore
currently do not have enough supporting evidence to be
included in the Celera database.
Our objective was to improve the current understanding of
the completeness of the human transcriptome by establishing an
automated approach to identify and improve the annotation of
novel transcripts. Though we were able to deduct gene structure
without the use of human annotators, the data generated can also
be ultimately used for further manual annotation, as performed
for RefSeqs. The approach chosen should be easily scaled up to
validate all available ab initio predictions. Moreover, all
identified novel transcripts have been deposited in Celera’s
CDS database and used to design TaqMan Gene Expression
Assays and were included in our Human Genome Survey
Microarray. All sequences have been deposited in public
databases.
RT-PCR coupled with sequencing of the generated ampli-
cons was our method of choice for validation because of our
need to determine gene structure clearly. However, it was
obvious that using this approach solely would be extremely
costly and time consuming and could result in lower validation
yields. To address the latter problem we decided to run our RT-
PCR on pools of three different tissue mRNAs, thereby
reducing the number of reactions that needed to be run. More
importantly, we decided to test several prioritization approaches
that would filter the predictions to be processed through the RT-
PCR pipeline and increase their validation yields.
Four different approaches were used to predict which
sequences would have the highest validation rate by RT-PCR:
expression on microarrays, presence of a Panther protein
classification, similarity to dog or mouse genomic fragments, or
colocalization with an MPSS tag. Of the four methods, we
determined that microarray gene expression profiling on 15
single tissues provided the most accurate method for filtering
out ab initio gene predictions (providing a 32% validation rate)
and that the combined platform of microarray filtering with RT-
PCR and amplicon sequencing as the final validation tool is
ideal because it provides the most sequence information while
enabling cost-effective gene processing.
The 32% yield obtained is affected by several factors,
notably cross-hybridization on the arrays; several of the
predictions were quite short, preventing the design of highly
specific probes. Another factor that can affect the validation rate
is RT-PCR false positives caused by the highly automated
nature of the process. Recently, Wu et al. [27], validating rat
predictions with RT-PCR and direct sequencing, were able to
increase their validation yields from 44 to 59% by repeating the
RT-PCR using the same primers but slightly modifying the PCR
conditions.
Of the 7252 sequences selected for prioritization that were
processed by RT-PCR combined with sequencing, we identified
847 novel transcripts—an overall validation rate of 12% for ab
initio gene predictions with little supporting evidence for their
existence.
Our final validation rate of 12% is lower than that found in
other recent RT-PCR and sequencing studies, such as a study
validating 230 of the novel Genscan-predicted genes on
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other recent studies validating predictions generated using the
recently derived dual genome-prediction program TWINSCAN
[13] in humans [26] and rat [27], which yielded rates of 62 and
44–59%, respectively.
These differences can be largely explained by the prediction
algorithms used to identify the genes. The new dual-genome
predictors have been shown to outperform single genome
predictors [33]; however, they do require sequences of related
organisms separated by appropriate evolutionary distances to be
fully effective. Additionally, these studies did not necessarily
focus on predictions supported by weak experimental evidence
or by no experimental evidence at all. For example, the 62%
validation rate in Guigo et al. [26] drops to 20–25% when
predictions that do not overlap with Ensembl predictions were
validated. It is worth noting, however, that in the rat study the
validation rate was indeed for predictions that did not overlap
with the Ensembl set [27], but were homologous to human
HGMD genes.
For the Das et al. study [10], the work did not focus solely
on spliced transcripts but also took into account unspliced
transcripts that may or may not be real. When only spliced
transcripts in this study are counted, the validation rate drops
from 27 to 13.5%—a rate that is very similar to our
unfiltered rate. When we added filtering mechanisms to our
pipeline, our validation rates went up. For example, ab initio
gene predictions that had more than 50% similarity to dog
and/or mouse sequences subsequently validated at a rate of
15%, and ab initio gene predictions that gave a positive
signal on the microarray subsequently validated at a rate of
32%.
Given that there are more than 60,000 or so (after filtering
overlapping predictions) ab initio gene predictions that remain
to be processed, we predict that by employing a pipeline
similar to the one described here—using microarrays on 15
single tissues to filter gene predictions before proceeding to
RT-PCR validation on tissue pools and sequencing—about
4000 to 5000 new human genes remain to be discovered. This
number, however, may be slightly overestimated, since only
21,000 (including the 7252 validated in this paper) of the
remaining 60,000 have weak evidence supporting their
existence; the remaining ones are either single-exon predic-
tions or multiexon predictions with no supporting evidence
(Supplemental Data File 7), which will likely exhibit lower
validation rates.
Our RT-PCR and sequencing pipeline throughput averaged
50 96-well plates per week and could be easily increased to 200
per week by switching from a 96-well to a 384-well format,
meaning that the remaining 60,000 could theoretically be
processed in 3 to 4 months. Furthermore, we determined that 4
of the 10 tissue pools (pools 1, 2, 3, and 6 in Supplemental Data
File 1) contained more than 90% of the genes that were
successfully validated; therefore, reagent costs could be reduced
and throughput could be maximized by focusing exclusively on
these four tissue pools.
Mapping the transcriptome has been a challenging task
underscored by the widely divergent predictions of the numberof genes in the human genome. Although the number seems to
have settled in the range of 20,000 to 25,000 [3], recent studies
using tiling microarrays have indicated the existence of
significant transcription outside of known genes [23,24].
Though a lot of these identified new genes could potentially
be noncoding, a subset will surely be protein-coding genes that
have not been predicted by current computational approaches.
Tiling arrays, by their parallel nature, are uniquely suited to
these types of genome-wide analysis; nevertheless, they do not
obviate the need for RT-PCR and/or RACE for further
validation and characterization of gene structure. This was
demonstrated by Cheng et al. [24], who used both approaches in
their 10-chromosome-wide study. Similarly in our case, as
opposed to relying exclusively on computer predictions, or
microarray profiling, our combined approach allowed us to gain
considerable insights into the novel genes’ structure; for
example 238 new exons were identified and nearly 60% of all
validated predictions were extended by our high-throughput
RACE pipeline, indicating the ends had been mispredicted by
the software-based prediction methods. Additionally, because
our microarray profiling was done on individual tissues we were
able to determine the novel transcripts’ tissue distribution
(Supplemental Data File 2).
The distribution of the alternatively spliced transcripts was
also interesting. Most of the variants were identified in the
cancer and fetal pools (38 and 57%, respectively). The numbers
for the cancer pools make intuitive sense since alternative
splicing has been associated with cancer tissues [31]; however,
we were surprised by the levels identified in the fetal pools. In
retrospect though, since fetal tissues are more than likely
undergoing significant growth and developmental changes, they
would likely require novel gene functions provided by
alternative splicing events. This latter explanation is further
strengthened by the significant difference in the distribution of
alternative splicing events between normal and fetal tissues (5%
vs 58%, respectively). We believe that our genome-wide results
strongly suggest that alternative splicing is an important
element in the early development process.
Overall, splice variants were identified for 30% of the
validated genes. This result is slightly below the current
estimates that 40–60% of human genes are alternatively spliced
[34,35]; however, the discrepancy could be due to the
confounding effect of using tissue pools in our RT-PCR
pipeline.
In our experience, and based on the previous work cited here,
we believe that experimentally filtering de novo predictions
generated by single or dual genome predictors (or a combina-
tion of both) followed by systematic validation using an
automated RT-PCR/amplicon sequencing pipeline will be a
cost-effective approach to characterizing the transcriptome
further. In addition to providing a better picture of the status
of the human transcriptome, identifying and annotating a
complete and accurate set of human genes have important
implications for large-scale genetic research that begins with
known human genes, for example gene expression surveys
using microarrays and gene mapping experiments within
genomic regions linked to disease through linkage mapping
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significant effect on the biological process being studied, they
will be missed because they are simply not represented on the
array or in the annotation of the genomic region being studied.
The addition of these genes (and their respective homologies,
gene structure, and splice forms) to the annotation of the human
genome is an important step in ensuring that future biological
research is complete.
Materials and methods
Identifying gene predictions and promotes
Approximately 98,454 ab initio gene predictions from three prediction
programs—Genscan [36], GRAIL2 [37], and FgenesH [38]—did not have
exon overlap with existing curated Celera transcripts (i.e., they had
insufficient evidence to be instantiated as genes by our manual curators).
From these, 39,951 predictions with very weak similarity to existing protein
or EST sequences were initially selected for further validation. In many
cases, the software programs produced overlapping or redundant gene
predictions. To avoid redundant validation, gene predictions with exon
overlap were clustered and a single cluster representative was chosen;
pseudogenes were also filtered out at this stage. Cluster representatives were
selected primarily to maximize the number of exons and secondarily to
maximize the length of the gene prediction. After clustering, approximately
31,000 gene predictions emerged, made up of 10,000 single-exon gene
predictions and 21,000 multiexon gene predictions. The 21,000 multiexon
gene predictions were then considered to be candidates for RT-PCR
validation (Supplemental Data File 7).
Prioritizing predictions
The complete process for prioritizing and processing ab initio gene
predictions is diagrammed in Fig. 2.
Similarity to dog and mouse genomic fragments. Gene predictions were
first ranked based on their percentage of similarity (over 50% of their
length) at the DNA level to dog and mouse genomic fragments. PredictionsFig. 2. Bioinformatic and experimental approaches for prioritizing and validating ab i
to RT-PCR and sequencing using four different methods: Panther classification, MP
mouse genes. Some ab initio gene predictions were subjected to more than one method
to be validated by RT-PCR and sequencing were also subjected to 5′ and 3′ RACEwere binned by percentage similarity: N50%, 30 to 50%, 15 to 29%, and less
than 15% similarity. Of the predictions (mostly from the higher similarity
bins) 7252 were chosen for RT-PCR validation. This method was based on
the hypothesis that exons from ab initio predictions with significant
similarity to dog and mouse sequences have a higher probability of being
real exons.
Panther protein classification. All 21,000 ab initio predictions were also
processed through Celera’s Panther protein classification software pipeline [29].
The software pipeline was able to assign a classification to 1684 of the
predictions, and 1127 of those predictions were processed through the RT-PCR
validation pipeline.
Colocalization with MPSS tags. Three hundred thirteen ab initio predictions
of the 7252 nonredundant predictions also colocalized with a 17-mer MPSS tag
[30] from the 88,782 present in Celera’s database. MPSS tags were mapped to
the Celera human genome, and only perfectly mapped tags were used for this
analysis. AnMPSS tag was considered “colocalized”with a predicted gene if the
tag overlapped with the exon region of the predicted gene. The RT-PCR
validation rates of these predictions were analyzed independently.
Detection of expression by microarrays. Additionally, the expression pat-
terns of 557 randomly chosen predictions (of the total 7252 predictions)
were analyzed using microarrays. Three to six 60-mer probes for each ab
initio gene prediction were designed using a custom bioinformatics pipeline
developed at Applied Biosystems (Foster City, CA, USA). These probes
were custom synthesized onto Agilent 60-mer Custom in Situ Oligonucle-
otide Microarrays (8.4K (G2508A) and 22K (G2509A); Agilent, Palo Alto,
CA, USA). mRNA expression values were generated from the arrays using
dual-color experiments in which Stratagene Universal human reference RNA
(Stratagene, La Jolla, CA, USA) was labeled with Cy3, and mRNA from 15
individual tissues (BD Biosciences, Palo Alto, CA, USA) was labeled with
Cy5. RNA integrity was confirmed with the Agilent bioanalyzer or 12.5%
Mops denaturing agarose gel electrophoresis. A two-step amino allyl–cDNA
labeling strategy [39] was used to label the RNA samples with the following
modifications: briefly, 1 μg mRNA and 20 μg of Universal total RNA was
used for each array. Bacterial RNAs (bioB, bioC, bioD, Cre, Dap, and Phe)
were spiked into the RNA to monitor the cDNA synthesis efficiency as well
as the hybridization success. cDNA synthesis was primed with a mixture of
oligo(dT) primers and random nanomers. Cy3- and Cy5-labeled cDNAsnitio gene predictions. Ab initio gene predictions were prioritized for progression
SS tag colocalization, microarray analysis, and level of similarity to dog and/or
of prioritization. Most predictions that passed the prioritization step and went on
analysis.
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Piscataway, NJ, USA). The incorporation of Cy3 and Cy5 was monitored
using a scanning UV spectrophotometer (200–600 nm). Hybridization,
washing, array scanning, and data extraction systems were performed
according to the Agilent Technologies user’s guide. A minimum of three
chip replicates were used for each tissue.
A gene was called present on the array if 69% of all probes representing
that gene on all replicates gave expression levels above a determined
threshold. This 69% cutoff was derived by comparing the gene expression
levels of a subset of positive and negative control genes as determined by
quantitative real-time PCR (TaqMan Gene Expression Assays; Applied
Biosystems) and microarray experiments. These results were used to identify
the average expression level at which array results were likely to correlate
with TaqMan results. The threshold was calculated using two approaches. The
first was a background-oriented algorithm that calculates a noise threshold
level based on mean and standard deviation values that do not change at a
certain low noise level range [40]. The second approach used the signal
generated by random 60-mer negative controls to help determine the threshold
above which we would call a gene absent or present. The threshold was
determined to be the mean signal generated by the random oligos plus 2
standard deviations. These oligos were designed to have no homology to
human sequences (as determined by BLAST) and this fact was subsequently
validated by profiling their expression pattern on microarrays using mRNA for
17 different tissue sources. Any outliers were removed from the set of controls
(data unpublished). Both approaches gave similar thresholds, and the method
based on the negative controls was predominantly used to generate the results
presented in this paper. Additionally, the ratio of the Cy5 to Cy3 channel was
used to determine tissue distribution.
RT-PCR
cDNA preparation. Pooled total RNAwas made from equal amounts of each
human tissue listed in Supplemental Data File 1. In addition, each pool was
spiked with RNA from bioC (100 pM Escherichia coli (Migula)), Cre (10 pM
bacteriophage P1 Cre gene for recombinase protein), and pheB (1 pM Bacillus
subtilis phenylalanine biosynthesis-associated protein) as positive controls. A
reaction with no template was used as the negative control. cDNAs were
constructed from these pools (100 μg) using the High Capacity cDNA Archive
Kit (Applied Biosystems).
SYBR green PCR. Primers (2.5 μl of 2.5 μM) were mixed with 0.15 μl of the
cDNA preparation and 6.25 μl of SYBR Green PCR Master Mix (Applied
Biosystems) in a total volume of 12.5 μl. Positive control primers for bioC, Cre,
and pheB were included. A reaction without template was used as the negative
control.
Forward and reverse 10 μM gene-specific primers (Biosource Interna-
tional, Camarillo, CA, USA) were combined with the cDNA pools and
reactions were carried out in ABI Prism 96-well optical reaction plates
(Applied Biosystems) that were sealed with optical adhesive covers (Applied
Biosystems) and thermal cycled on the GeneAmp PCR System 9700
(Applied Biosystems) using the following cycling parameters: 10 min at
95°C; 40 cycles of 95°C for 30 s, 64°C for 45 s, 68°C for 90 s; and 10 min
at 68°C.
Fluorescence end-point reads of SYBR/ROX were determined using an ABI
Prism 7900HT sequence detection system (Applied Biosystems). In addition,
one plate of every five was loaded on a 4% gel as a control, and data were
documented using a Gel Doc 2000 gel documentation system (Bio-Rad
Laboratories, Hercules, CA, USA).
RT-PCR was conducted on 10 different pools of cDNAs derived from
multiple tissues (Supplemental Data File 1).
PCR cleanup. Single-stranded DNAwas degraded using 2.5% exonuclease I
(USB, Cleveland, OH, USA) and dephosphorylated using 25% shrimp alkaline
phosphatase (USB) in 72.5% T10E0.1 buffer (Teknova, Half Moon Bay, CA,
USA) The SYBR green reaction plate was heat sealed with Eazy Peel AB-3739
(Abgene, Rochester, NY, USA). After a quick spin down, the plate was placed
into a 96-well GeneAmp PCR System 9700 (Applied Biosystems) and run for
60 min at 37°C, and then 15 min at 72°C.Sequencing
Reactions from the cleaned PCR plates were sequenced using the original
forward and reverse primers. Reactions were carried out using 5 μl of a mix
containing 60% BigDye Mix from the BigDye Terminator Cycle Sequencing
Ready Reaction Kit, version 1.0 (Applied Biosystems), 30% PCR H2O, and 10%
5× sequencing buffer (Applied Biosystems), combined with 4 μl of PCR product
and 1 μl of 3.3 μMprimer. The 96-well PCR plates containing these reactions were
sealed, spun down, and placed on the 96-Well GeneAmp PCR System 9700 for 1
min at 96°C and then 50 cycles of 96°C for 1 min, 52°C for 10 s, 60°C for 4 min.
Sequencing reactions were cleaned using the Performa DTR Gel Filtration
Systems 96 (Edge BioSystems, Gaithersburg, MD, USA) according to
manufacturer’s specifications. The collection plates were dried down using
the SpeedVac concentrator system (Savant Instruments, Holbrook, NY, USA),
rehydrated in Hi-Di Formamide (Applied Biosystems), and run on the ABI
Prism 3700 DNA analyzer (Applied Biosystems) using POP-6 performance-
optimized polymer (Applied Biosystems).
Primer design, data storage, and validation criteria
RT-PCR primers were designed using Primer3 software [41]. RT-PCR
primers were tiled across the entire predicted transcript with a target amplicon
size of 300–500 bp and 50 to 100 bp overlap of the amplicons. Ten primer pairs
were generated for each tile and compared against all human Celera and public
transcripts using the BLAST program. On average, 90% of the predicted
transcripts were covered by primers. The primer pairs with the lowest predicted
cross-hybridization were picked. Cross-hybridization was estimated based on
the sequence homology of the primers to the transcripts, and mismatches toward
the 3′ end of a primer were considered more detrimental (i.e., weighted higher)
than mismatches in the middle or at the 5′ end. Sequence reads were generated
using the RT-PCR primers as sequencing primers. Bases were called using Phred
software [42,43]. Sequences were curated using in-house software and low-
quality nucleotides were masked. The resulting sequence reads were assembled
using Phrap assembly software [44].
The assembled sequence reads were then aligned to genomic sequences using
Celera’s proprietary in-house EstMapper software to determine their gene structure.
To be determined “validated” a transcript was required to have at least one exon/
intron boundary when the corresponding transcript was aligned to the genome. The
one exon/intron boundary limit was chosen because so many of the ab initio gene
predictions were very small (b500 bp) and likely contained only one exon.
Following RT-PCR and direct sequencing, assembled sequences with
corresponding genomic alignments were stored in an ORACLE database
(HercDB). This database was designed and developed to serve as a hub for the
data generated by the various assay design and data capture pipelines. HercDB
stored and tracked all information generated by the project, including transcript
sequences, primer designs, amplicon/contig sequences, and validated prediction
sequences.
RACE
A subset of gene predictions that had been validated by RT-PCR and
sequencing were subjected to RACE [45] analysis to obtain sequences beyond
their predicted 5′ and 3′ ends. RACE was performed using Marathon cDNA and
Advantage 2 polymerase mix (BD Biosciences) in accordance with the
manufacturer’s instructions except that all reactions were scaled down to 10
μl. Marathon cDNAs were pooled to match the compositions of templates used
for RT-PCR as described above. RACE was first carried out using a transcript-
specific primer (P1) in combination with an adaptor primer (AP1) and at least
one template pool from which the transcript was validated by RT-PCR. Primary
RACE product was diluted 1:15 for secondary RACE, which used a nested
transcript-specific primer (N1) in combination with the other adaptor primer
(AP2). The melting temperature of each primer typically ranged from 69 to
71°C. Primary RACE reactions utilized the following method: 3 min at 94°C; 5
cycles of 5 s at 94°C, 4 min at 72°C; 5 cycles of 5 s at 94°C, 10 s at 70°C, 4 min
at 72°C; 25 cycles of 5 s at 94°C, 10 s at 68°C, 4 min at 72°C; 7 min at 72°C.
Secondary RACE reactions utilized the following method: 3 min at 94°C; 25
cycles of 5 s at 94°C, 10 s at 68°C, 4 min at 72°C; 7 min at 72°C. Secondary
RACE products were treated with exonuclease I and SAP as described above
444 P.M. Brzoska et al. / Genomics 87 (2006) 437–445and sequenced directly with N1 primer and a nested sequencing primer (S1) as
described above.
Alternative splicing bioinformatics pipeline
The algorithm described below was developed to use the data generated
from the RT-PCR and direct sequencing experiments and perform an automatic
search for alternative splicing events; 847 validated gene predictions were
analyzed by this method. Several rounds of manual curation of results were
performed and pipeline parameters were adjusted accordingly:
1. Collect contiguous assembled sequences (contigs) per tissue pool per
validated gene prediction.
2. Use above contigs to mine a database for corresponding genomic alignments
showing a “split” of the contig in a following manner: e1(p1, p2), e2(p3, p4),
e3(p5, p6), where (a) e1, e2, and e3 are three exons derived from a contig; (b)
pX are the positions of individual exons on a genome and p1 b p2 b p3 b
p4 b p5 b p6; and (c) p3 − p2 N 15 and p5 − p4 N 15 (“introns”).
3. Alternative splicing events are defined as follows: (a) “Missing/extra exon”:
if tA = e1a + e2a + e3a and tB = e1b + e2b, then e1a(p1,p2) = e1b(p1,p2) and
e3a(p5,p6) = e2b(p3,p4), where tA and tB are two alternative forms arising
from a validated gene. (b) “Alternative 5′-exon position”: if tA = e1a + e2a
and tB = e1b + e2b, then [e2a(p3) − e1a(p3)] N 10, where tA and tB are
defined as in 3(a) above. (c) “Alternative 3′-exon position”: if tA = e1a + e2a
and tB = e1b + e2b then [e1a(p3) − e2a(p3)] N 10, where tA and tB are
defined as in 3(a) above.
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